Jonathan Young, Chief Operating Officer at Akero Therapeutics, Inc. (AKRO), sold 40,000 shares at $30.15 ($1.2M) on 2024-10-14, disclosed to the SEC on 2024-10-16.
Scheduled sale ($1.2M) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| AKRO | SELL | 2025-09-04 | $705K | — | Filing → |
| AKRO | SELL | 2025-08-13 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $159K | — | Filing → |